Eli Lilly Aktie
| 768,44USD | 11,01USD | 1,45% |
WKN: 858560 / ISIN: US5324571083
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 89,61 |
| Lilly Endowment, Inc. | 10,21 |
| Lilly Endowment, Inc. | 10,21 |
| The Vanguard Group, Inc. | 7,54 |
| Vanguard Group, Inc. (Subfiler) | 7,39 |
| PNC Financial Services Group, Inc. (13F Subfiler) | 5,41 |
| PNC Bank, NA (Investment Management) | 5,39 |
| State Street Corp. | 3,57 |
| Vanguard Total Stock Market ETF | 2,84 |
| Fidelity Management & Research Co. LLC | 2,53 |
| BlackRock Fund Advisors | 2,46 |
| Vanguard 500 Index Fund | 2,20 |
| Capital Research & Management Co. (World Investors) | 2,14 |
| T Rowe Price Associates, Inc. (13F Subfiler) | 2,09 |
| BlackRock Institutional Trust Co. NA | 1,87 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 33 625 | 35 000 | 35 000 | 39 000 | 43 000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,66 | 0,70 | 0,81 | 0,73 | 0,79 |
Bilanz (in Mio. USD) - Aktiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 13 710 | 17 462 | 18 452 | 18 035 | 25 727 |
| Summe Anlagevermögen | 25 577 | 29 171 | 30 354 | 31 455 | 38 279 |
| Summe Aktiva | 39 286 | 46 633 | 48 806 | 49 490 | 64 006 |
Bilanz (in Mio. USD) - Passiva
| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 36 587 | 40 808 | 39 651 | 38 714 | 53 143 |
| Summe Eigenkapital | 2 699 | 5 825 | 9 155 | 10 775 | 10 864 |
| Summe Passiva | 39 286 | 46 633 | 48 806 | 49 490 | 64 006 |
Adresse
| Lilly Corporate Center, 46285 Indianapolis | |
| Telefon | +1 (317) 276-2000 |
| Internet | http://www.lilly.com |
Management
|
Alonzo Weems
Executive VP, Chief Ethics & Compliance Officer |
|
Anat Hakim
Secretary, Executive VP & General Counsel |
|
Andy Vicari
Senior Director & US Brand Leader-Insulins |
|
Anne E. White
Executive Vice President-Lilly Neuroscience |
|
Christian Nguyen
VP-Global Patient Outcomes & Real World Evidence |
|
Daniel M. Skovronsky
Chief Scientific Officer & Executive VP |
|
David A. Ricks
Chairman, President & Chief Executive Officer |
|
David Hyman
Chief Medical Officer |
|
Diogo Rau
Executive VP, Chief Information & Digital Officer |
|
Donald A. Zakrowski
Chief Accounting Officer & Vice President-Finance |
|
Edgardo Hernandez
President-Manufacturing Operations & Senior VP |
|
Eric Dozier
Executive VP-Human Resources & Diversity |
|
Gabrielle G. Greene-Sulzberger
Independent Director |
|
Ilya Yuffa
Senior VP & President-Lilly Bio Medicines |
|
Jacob S. van Naarden
Executive Vice President |
|
Jamere Jackson
Independent Director |
|
Jennifer Oleksiw
Global Chief Customer Officer & Vice President |
|
Joe Fletcher
Investor Relations Contact |
|
Jon Erik Fyrwald
Independent Director |
|
Jon R. Moeller
Director |
|
Juan Ricardo Luciano
Lead Independent Director |
|
Katherine Baicker
Independent Director |
|
Kim Macko
Head-Global Brand Development |
|
Kimberly H. Johnson
Independent Director |
|
Laura A. Lane
Vice President |
|
Lucas E. Montarce
Chief Financial Officer & Executive Vice President |
|
Mark Genovese
Senior Vice President-Immunology Development |
|
Mary Lynne Hedley
Independent Director |
|
Melissa Seymour
Executive Vice President-Global Quality |
|
Nathaniel R. Miles
Vice President-Strategic Initiatives |
|
Patrik Jonsson
EVP, President-Lilly Diabetes & Obesity |
|
Ralph Alvarez
Independent Director |
|
Robert Conley
Development Leader-Neuroscience |
|
Robert J. Heine
Vice President-Medical Affairs |
|
Ruth Gimeno
Vice President |
|
Thomas Fuchs
Chief Artificial Intelligence Officer |
|
Travis Coy
VP, Head-Transactions & Business Development |
|
William G. Kaelin
Independent Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
